# Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

> **NCT00788957** · PHASE1,PHASE2 · COMPLETED · sponsor: **NantBioScience, Inc.** · enrollment: 177 (actual)

## Conditions studied

- Colon Cancer
- Colorectal Cancer
- Gastrointestinal Cancer
- Metastatic Colorectal Cancer
- Rectal Cancer

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Ganitumab
- **DRUG:** Rilotumumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00788957
- **Lead sponsor:** NantBioScience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-27
- **Primary completion:** 2010-07-23
- **Final completion:** 2010-07-23
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00788957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00788957, "Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00788957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*